151751-Najiba-Chargi

269 Systemic therapy: the prospective PLATISMA study S2. Parameter estimates of cisplatin in the pharmacokinetic model with skeletal muscle mass imputed as covariate on CLfree, CLbound, and Vbound Parameter Estimate (RSE %) CL free (L/h) Effect of SMM 12.2 (4.2) 0.313 (23.8) V free (L) 14.4 (5.7) Q (L/h) 8.99 (9.1) V p (L) 307 (11.3) CL bound (L/h) Effect of SMM 0.644 (4.6) 0.842 (17.1) V bound (L) Effect of SMM 32 (4.8) 0.67 (14) Inter-individual variability %CV (RSE %) CL free (L/h) 12.7 (18.8) V free (L) 27.3 (18) CL bound (L/h) 15.9 (30.6) V bound (L) 16.5 (9.9) Proportional residual unexplained variability %CV (RSE %) Free cisplatin 17.1 (9.4) Bound cisplatin 6.1 (10.8) CLfree, clearance of free cisplatin; Vfree, volume of distribution of free cisplatin; Q, intercompartmental clearance; Vp, volume of distribution of the peripheral compartment of free cisplatin; CLbound, clearance of bound cisplatin; Vbound, volume of distribution of bound cisplatin; RSE, relative standard error; %CV, percentage coefficient of variation 14